Epidemiology and Outcomes of Recurrent <i>C Difficile</i> Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study
Recurrent CDI occurred in 10% of HCT recipients in the early posttransplant period and was associated with use of metronidazole. Further study is needed to characterize risk factors for recurrent CDI among HCT recipients to guide use of agents aimed at preventing recurrence.
Authors
- Paul A. Carpenter (ORCID: https://orcid.org/0000-0002-5021-0714)
- Eduardo Sanchez (ORCID: https://orcid.org/0009-0006-6917-7156)
- Zahra Kassamali Escobar (ORCID: https://orcid.org/0000-0003-1916-0269)
- Steven A. Pergam (ORCID: https://orcid.org/0000-0002-6333-5196)
- Frank Tverdek (ORCID: https://orcid.org/0000-0001-7510-5470)
- Elizabeth M. Krantz
- Masumi Ueda (ORCID: https://orcid.org/0000-0003-2277-1976)
- Catherine Liu (ORCID: https://orcid.org/0000-0002-7532-4822)
- Emily A. Rosen (ORCID: https://orcid.org/0000-0002-1378-8859)
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Banner - University Medical Center Tucson (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1093/ofid/ofae570
- Citations
- 1
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Norges Idrettshøgskole
- National Institutes of Health
- National Cancer Institute, Cairo University
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases